文献速递心脏核医学

PET在疑似心脏结节病评估中的预后价值

The prognostic value of positron emission tomography in the evaluation of suspected cardiac sarcoidosis.
PubMed 文献 · J Nucl Cardiol · 2021-09-09

本研究回顾性分析了197例未接受免疫抑制治疗、因已知或疑似心脏结节病(CS)行18F-FDG PET扫描的患者,主要终点为室性心律失常(VT/VF)或死亡时间。中位随访531天,41例达到主要终点;多因素分析显示左心室射血分数(LVEF)、VT/VF病史和静息总评分(SRS)为独立预测因素,而PET的FDG摄取定量与定性指标均未预测临床事件。

要点

  • 未接受免疫抑制治疗的疑似CS患者中,LVEF、VT/VF病史和SRS与不良结局相关。
  • PET的FDG摄取定量与定性指标未预测室性心律失常或死亡。
  • 研究提示在此类未治疗人群中,PET代谢指标预后价值有限。

核心结论

  • 在未接受免疫抑制治疗、因已知或疑似CS行PET扫描的患者中,LVEF、VT/VF病史和SRS与 adverse clinical outcomes 相关,而FDG摄取指标未预测临床事件。

研究设计与样本

  • 回顾性分析197例未接受免疫抑制治疗、因已知或疑似CS行18F-FDG PET扫描的患者,主要终点为VT/VF或死亡时间。

主要发现

  • 中位随访531天(IQR 309–748天),41例患者达到主要终点。
  • 多因素Cox回归显示LVEF(HR 0.98,95% CI 0.96–0.99,P=0.02)、VT/VF病史(HR 4.19,95% CI 2.15–8.17,P<0.001)和SRS(HR 1.06,95% CI 1.02–1.12,P=0.01)预测主要终点。
  • PET的FDG摄取定量与定性指标均未预测临床事件。

临床怎么用

  • 对未接受免疫抑制治疗的疑似CS患者,评估预后时可关注LVEF、VT/VF病史和SRS,而非依赖PET的FDG摄取指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the prognostic value of positron emission tomography (PET) imaging in patients undergoing evaluation for known or suspected cardiac sarcoidosis (CS) while not on active immunotherapy. BACKGROUND: Previous studies have attempted to identify the value of PET imaging to aid in risk stratification of patients with CS, however, most cohorts have included patients currently on immunosuppression, which may confound scan results by suppressing positive findings. METHODS: We retrospectively analyzed 197 patients not on immunosuppression who underwent 18F-fluorodeoxyglucose (FDG) PET scans for evaluation of known or suspected CS. The primary endpoint of the study was time to ventricular arrhythmia (VT/VF), or death. Candidate predictors were identified by univariable Cox proportional hazards regression. Independent predictors were identified by performing multivariable Cox regression with stepwise forward selection. RESULTS: Median follow-up time was 531 [IQR 309, 748] days. 41 patients met the primary endpoint. After stepwise forward selection, left ventricular ejection fraction (LVEF) (HR 0.98, 95% CI 0.96-0.99, P = 0.02), history of VT/VF (HR 4.19, 95% CI 2.15-8.17, P < 0.001), and summed rest score (SRS) (HR 1.06, 95% CI 1.02-1.12, P = 0.01) were predictive of the primary endpoint. Quantitative and qualitative measures of FDG uptake on PET were not predictive of clinical events. CONCLUSIONS: Among untreated patients who underwent PET scans to evaluate known or suspected CS, LVEF, history of VT/VF, and SRS were associated with adverse clinical outcomes.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Patel VN, Pieper JA, Poitrasson-Rivière A, et al. The prognostic value of positron emission tomography in the evaluation of suspected cardiac sarcoidosis. J Nucl Cardiol. 2021. PMID: 34505261. doi:10.1007/s12350-021-02780-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。